As 2026 unfolds, healthcare’s dealmakers are moving fast, reshaping the industry through bold acquisitions that fuse innovation, scale, and strategy. From medtech giants expanding their reach to biopharma leaders doubling down on rare disease and diagnostics, this year’s mergers signal a new era of integrated care and data‑driven growth. Here are the five biggest healthcare mergers making headlines so far.
Boston Scientific and Penumbra – $14.5B
The year’s largest medtech deal so far. Boston Scientific scoops up Penumbra in a $14.5B move that instantly reshapes the neurovascular and thrombectomy landscape. Think scale, synergy, and a pipeline that suddenly looks a lot more formidable.
Waters Corporation and BDS Business – $13B
A diagnostics heavyweight play. Waters adds BDS in a $13B stock transaction that expands its analytical instrumentation footprint and tightens its grip on the life sciences tools market.
Danaher and Masimo – ~$9.9B
Danaher continues its precision‑health shopping spree, pulling Masimo’s monitoring tech into its diagnostics ecosystem. At nearly $10B, this one signals a serious bet on connected, continuous patient monitoring.
Biogen and Apellis – ~$5.6B
Biogen goes deeper into immunology and rare disease with a $41/share + CVR deal for Apellis. The complement‑pathway portfolio is the prize, and it’s a strategic one.
BioMarin and Amicus – ~$4.8B
Rare‑disease consolidation continues. BioMarin acquires Amicus for $4.8B, adding a commercial‑stage therapy and strengthening its already dominant position in genetic disease.
